Northern Trust
BCAX

Northern Trust’s Bicara Therapeutics BCAX Stock Holding History

Northern Trust’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.08M Buy
255,571
+18,464
+8% +$318K ﹤0.01% 2449
2025
Q4 		$3.99M Sell
237,107
-23,759
-9% -$406K ﹤0.01% 2604
2025
Q3 		$4.12M Buy
260,866
+29,253
+13% +$327K ﹤0.01% 2620
2025
Q2 		$2.15M Buy
231,613
+77,401
+50% +$922K ﹤0.01% 2940
2025
Q1 		$2.01M Sell
154,212
-4,831
-3% -$64.2K ﹤0.01% 2926
2024
Q4 		$2.77M Buy
+159,043
New +$3.31M ﹤0.01% 2839

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Northern Trust's BCAX Position: Q1 2026 in Review

Northern Trust increased its Bicara Therapeutics (BCAX) stake by 7.8% in Q1 2026, buying an estimated $318K and bringing the position to 255,571 shares worth $5.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Northern Trust first reported a position in BCAX in Q4 2024 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Northern Trust held 255,571 shares of Bicara Therapeutics worth $5.08M as of Q1 2026.
  • Northern Trust bought 18,464 Bicara Therapeutics shares in Q1 2026, an estimated $318K.
  • Bicara Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2449 holding.
  • Northern Trust first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.